Personalized mRNA Cancer Vaccine Shows Promising Results in Phase 3 Melanoma Trial

An individualized mRNA cancer vaccine, intismeran, significantly reduced the relative risk of melanoma recurrence or death by 42% when added to existing treatment in patients with resected stage IIB-IV melanoma. Results from the Phase 3 INTerpath-001 trial abstract, presented at ESMO Congress 2026, indicate that 82% of patients receiving the combination were free from recurrence at two years, compared to 70% receiving pembrolizumab alone.